TRAJ46: A Protein in The Immune System (G28709)

Target Name: TRAJ46

NCBI ID: G28709

TRAJ46

Other Name(s): T cell receptor alpha joining 46

TRAJ46: A Protein in The Immune System

T cell receptor alpha joining 46 (TRAJ46) is a protein that plays a crucial role in the immune system. It is a type of protein known as a co-receptor, which means it is a partner to a primary receptor that recognizes a specific signal in the environment. T cells, also known as T lymphocytes, are a type of immune cell that play a vital role in protecting the body against infection and disease.

TRAJ46 is a protein that is expressed in many different tissues throughout the body, including the brain, spleen, heart, and lymphoid organs. It is a member of the T cell receptor alpha chain, which is a family of proteins that are involved in the development and activation of T cells. The alpha chain consists of four proteins: alpha-1, alpha-2, alpha-3, and alpha-4.

TRAJ46 is one of the proteins that is part of the alpha chain. It is a protein that is made up of 154 amino acids. It has a molecular weight of 19.1 kDa and a pI (peak of the inverse logarithm of the affinity for a protein) of 11.9 nM.

TRAJ46 is involved in the process of T cell activation. When a T cell encounters an antigen that it is able to recognize through its T cell receptor, it becomes activated. Activation involves a number of different steps, including the recognition of the antigen by the T cell receptor, the binding of the T cell receptor to the proteinTraj46, and the subsequent signaling of that interaction to the T cell.

TRAJ46 is also involved in the regulation of the immune response. It is a co-receptor for the T cell receptor alpha chain, which means that it is involved in the signaling process that occurs when the T cell receptor is activated. This signaling process is important for the development and activation of T cells, as well as for the regulation of other immune cells.

TRAJ46 is a potential drug target for researchers because it is involved in the immune system and has been shown to play a role in a number of different diseases. For example, studies have shown that people with certain types of cancer are more likely to have changes in the levels of TRAJ46 in their bodies than those without the disease. Researchers are also exploring the potential uses of TRAJ46 as a biomarker for certain types of cancer.

In addition to its potential as a drug target, TRAJ46 is also an interesting protein for research into the immune system. Its structure and function have been studied extensively, and its role in the immune response continues to be an area of active research.

Overall, T cell receptor alpha joining 46 (TRAJ46) is a protein that is involved in the immune system and has the potential to be a drug target or biomarker. Further research is needed to fully understand its role in the immune system and its potential uses in both research and medicine.

Protein Name: T Cell Receptor Alpha Joining 46

The "TRAJ46 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ46 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets